摘要
多发性骨髓瘤(multiple myeloma,MM)是以骨髓浆细胞克隆增殖的恶性肿瘤,约占血液肿瘤的10%。近年来随着新型药物的不断研发以及自体干细胞移植的开展,MM的预后得到显著改善,其中位生存期达到7~10年[1]。但大部分患者最终难免复发,MM仍不可治愈[2]。目前MM免疫治疗发展迅速,为治疗MM带来了更多的策略。
In recent years,with the development of new drugs and the development of autologous stem cell transplantation,the prognosis of multiple myeloma(MM)has been significantly improved.However,most patients will inevitably relapse eventually,and MM is still incurable.Currently,the rapid development of MM immunotherapy has brought more strategies for the treatment of MM.Immunotherapy is more specific and less toxic than traditional chemotherapy.This article will focus on the research progress of monoclonal antibody and adoptive cell therapy.
作者
梅舒翀
余莉
陈国安
MEI Shuchong;YU Li;CHEN Guoan
出处
《临床血液学杂志》
CAS
2019年第5期724-728,共5页
Journal of Clinical Hematology
基金
江西省卫计委科技计划(No:20181097)
